Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors-Reference-Cited by-同舟云学术

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors

Published:2013-04-25 Issue:5 Volume:4 Page:691-704
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Gillis Joanna L.¹,Selth Luke A.¹,Centenera Margaret M.¹,Townley Scott L.¹,Sun Shihua²,Plymate Stephen R.²³⁴,Tilley Wayne D.¹,Butler Lisa M.¹

Affiliation:

1. Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer Research Centre, University of Adelaide and Hanson Institute, Adelaide, South Australia, Australia.

2. Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

3. Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA.

4. Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alternative splicing in prostate cancer progression and therapeutic resistance;Oncogene;2024-04-24

2. Sigma1 Regulates Lipid Droplet–Mediated Redox Homeostasis Required for Prostate Cancer Proliferation;Cancer Research Communications;2023-10-30

3. HSP90.2 modulates 2Q2‐mediated wheat resistance against powdery mildew;Plant, Cell & Environment;2023-03-20

4. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models;Pharmacological Research;2023-03

5. The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer;Cancers;2022-10-05